aTYR PHARMA INC Stock-Based Compensation
aTYR PHARMA INC (ATYR) reported Stock-Based Compensation of $1.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-07
- aTYR PHARMA INC share-based payment arrangement, expense for the quarter ending 2026-06-30 was $1.15M, a 12.26% decline year-over-year.
- aTYR PHARMA INC share-based payment arrangement, expense for the quarter ending 2026-03-31 was $1.31M, a 10.95% increase year-over-year.
- aTYR PHARMA INC share-based payment arrangement, expense for the quarter ending 2025-12-31 was $1.21M, a 56.75% increase year-over-year.
- aTYR PHARMA INC share-based payment arrangement, expense for the quarter ending 2025-09-30 was $1.31M, a 73.80% increase year-over-year.
- aTYR PHARMA INC share-based payment arrangement, expense for fiscal 2025 was $5.00M, a 67.18% increase from fiscal 2024.
- aTYR PHARMA INC share-based payment arrangement, expense for fiscal 2024 was $2.99M, a 14.96% increase from fiscal 2023.
- aTYR PHARMA INC share-based payment arrangement, expense for fiscal 2023 was $2.60M, a 20.71% increase from fiscal 2022.
- aTYR PHARMA INC share-based payment arrangement, expense for fiscal 2022 was $2.15M, a 33.46% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.15M 10-Q · filed 2026-08-07 | $2.45M 10-Q · filed 2026-08-07 | $3.66M derived: sum of 3 quarters · filed 2026-08-07 | $4.97M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2026-03-31 | $1.31M 10-Q · filed 2026-05-15 | $2.51M derived: sum of 2 quarters · filed 2026-05-15 | $3.82M derived: sum of 3 quarters · filed 2026-05-15 | $5.13M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.51M derived: sum of 2 quarters · filed 2026-03-05 | $3.82M derived: sum of 3 quarters · filed 2026-08-07 | $5.00M 10-K · filed 2026-03-05 | |
| 2025-09-30 | $1.31M 10-Q · filed 2025-11-06 | $2.61M derived: sum of 2 quarters · filed 2026-08-07 | $3.79M 10-Q · filed 2025-11-06 | $4.56M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-06-30 | $1.30M 10-Q · filed 2026-08-07 | $2.48M 10-Q · filed 2026-08-07 | $3.25M derived: sum of 3 quarters · filed 2026-08-07 | $4.00M derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-03-31 | $1.18M 10-Q · filed 2026-05-15 | $1.95M derived: sum of 2 quarters · filed 2026-05-15 | $2.70M derived: sum of 3 quarters · filed 2026-05-15 | $3.43M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $770.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.52M derived: sum of 2 quarters · filed 2026-03-05 | $2.25M derived: sum of 3 quarters · filed 2026-03-05 | $2.99M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $752.00K 10-Q · filed 2025-11-06 | $1.48M derived: sum of 2 quarters · filed 2025-11-06 | $2.22M 10-Q · filed 2025-11-06 | $2.88M derived: sum of 4 quarters · filed 2026-03-05 | |
| 2024-06-30 | $727.00K 10-Q · filed 2025-08-07 | $1.47M 10-Q · filed 2025-08-07 | $2.13M derived: sum of 3 quarters · filed 2026-03-05 | $2.79M derived: sum of 4 quarters · filed 2026-03-05 | |
| 2024-03-31 | $740.00K 10-Q · filed 2025-05-07 | $1.40M derived: sum of 2 quarters · filed 2026-03-05 | $2.06M derived: sum of 3 quarters · filed 2026-03-05 | $2.72M derived: sum of 4 quarters · filed 2026-03-05 | |
| 2023-12-31 | $659.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.32M derived: sum of 2 quarters · filed 2026-03-05 | $1.98M derived: sum of 3 quarters · filed 2026-03-05 | $2.60M 10-K · filed 2026-03-05 | |
| 2023-09-30 | $664.00K 10-Q · filed 2024-11-07 | $1.32M derived: sum of 2 quarters · filed 2024-11-07 | $1.94M 10-Q · filed 2024-11-07 | $2.55M derived: sum of 4 quarters · filed 2025-03-13 | |
| 2023-06-30 | $658.00K 10-Q · filed 2024-08-13 | $1.28M 10-Q · filed 2024-08-13 | $1.88M derived: sum of 3 quarters · filed 2025-03-13 | $2.50M derived: sum of 4 quarters · filed 2025-03-13 | |
| 2023-03-31 | $619.00K 10-Q · filed 2024-05-02 | $1.22M derived: sum of 2 quarters · filed 2025-03-13 | $1.84M derived: sum of 3 quarters · filed 2025-03-13 | $2.36M derived: sum of 4 quarters · filed 2025-03-13 | |
| 2022-12-31 | $605.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.22M derived: sum of 2 quarters · filed 2025-03-13 | $1.74M derived: sum of 3 quarters · filed 2025-03-13 | $2.15M 10-K · filed 2025-03-13 | |
| 2022-09-30 | $615.00K 10-Q · filed 2023-11-09 | $1.13M derived: sum of 2 quarters · filed 2023-11-09 | $1.55M 10-Q · filed 2023-11-09 | $1.96M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-06-30 | $517.00K 10-Q · filed 2023-08-09 | $934.00K 10-Q · filed 2023-08-09 | $1.35M derived: sum of 3 quarters · filed 2024-03-14 | $1.79M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-03-31 | $417.00K 10-Q · filed 2023-05-09 | $831.00K derived: sum of 2 quarters · filed 2024-03-14 | $1.27M derived: sum of 3 quarters · filed 2024-03-14 | $1.67M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-12-31 | $414.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $856.00K derived: sum of 2 quarters · filed 2024-03-14 | $1.25M derived: sum of 3 quarters · filed 2024-03-14 | $1.61M 10-K · filed 2024-03-14 | |
| 2021-09-30 | $442.00K 10-Q · filed 2022-11-14 | $840.00K derived: sum of 2 quarters · filed 2022-11-14 | $1.20M 10-Q · filed 2022-11-14 | $1.54M derived: sum of 4 quarters · filed 2023-03-14 | |
| 2021-06-30 | $398.00K 10-Q · filed 2022-08-15 | $400.00K 10-Q · filed 2021-08-11 | $758.00K 10-Q · filed 2022-08-15 | $1.10M derived: sum of 3 quarters · filed 2023-03-14 | $1.42M derived: sum of 4 quarters · filed 2023-03-14 |
| 2021-03-31 | $360.00K 10-Q · filed 2022-05-10 | $700.00K derived: sum of 2 quarters · filed 2023-03-14 | $1.02M derived: sum of 3 quarters · filed 2023-03-14 | $1.40M derived: sum of 4 quarters · filed 2023-03-14 | |
| 2020-12-31 | $340.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $664.00K derived: sum of 2 quarters · filed 2023-03-14 | $1.04M derived: sum of 3 quarters · filed 2023-03-14 | $1.47M 10-K · filed 2023-03-14 | |
| 2020-09-30 | $324.00K 10-Q · filed 2021-11-12 | $702.00K derived: sum of 2 quarters · filed 2021-11-12 | $1.13M 10-Q · filed 2021-11-12 | $1.55M derived: sum of 4 quarters · filed 2022-03-15 | |
| 2020-06-30 | $378.00K 10-Q · filed 2021-08-11 | $801.00K 10-Q · filed 2021-08-11 | $1.23M derived: sum of 3 quarters · filed 2022-03-15 | $1.50M derived: sum of 4 quarters · filed 2022-03-15 | |
| 2020-03-31 | $423.00K 10-Q · filed 2021-05-14 | $848.00K derived: sum of 2 quarters · filed 2022-03-15 | $1.13M derived: sum of 3 quarters · filed 2022-03-15 | $1.64M derived: sum of 4 quarters · filed 2022-03-15 | |
| 2019-12-31 | $425.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $703.00K derived: sum of 2 quarters · filed 2022-03-15 | $1.21M derived: sum of 3 quarters · filed 2022-03-15 | $1.78M 10-K · filed 2022-03-15 | |
| 2019-09-30 | $278.00K 10-Q · filed 2020-11-13 | $787.00K derived: sum of 2 quarters · filed 2020-11-13 | $1.36M 10-Q · filed 2020-11-13 | $1.96M derived: sum of 4 quarters · filed 2021-03-24 | |
| 2019-06-30 | $509.00K 10-Q · filed 2020-08-13 | $1.08M 10-Q · filed 2020-08-13 | $1.68M derived: sum of 3 quarters · filed 2021-03-24 | $2.37M derived: sum of 4 quarters · filed 2021-03-24 | |
| 2019-03-31 | $571.00K 10-Q · filed 2020-05-12 | $1.17M derived: sum of 2 quarters · filed 2021-03-24 | $1.86M derived: sum of 3 quarters · filed 2021-03-24 | $3.07M derived: sum of 4 quarters · filed 2021-03-24 | |
| 2018-12-31 | $602.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $1.29M derived: sum of 2 quarters · filed 2021-03-24 | $2.50M derived: sum of 3 quarters · filed 2021-03-24 | $3.43M 10-K · filed 2021-03-24 | |
| 2018-09-30 | $690.00K 10-Q · filed 2019-11-14 | $1.90M derived: sum of 2 quarters · filed 2019-11-14 | $2.83M 10-Q · filed 2019-11-14 | $5.96M derived: sum of 4 quarters · filed 2020-03-26 | |
| 2018-06-30 | $1.21M 10-Q · filed 2019-08-14 | $2.14M 10-Q · filed 2019-08-14 | $5.27M derived: sum of 3 quarters · filed 2020-03-26 | $6.46M derived: sum of 4 quarters · filed 2020-03-26 | |
| 2018-03-31 | $928.00K 10-Q · filed 2019-05-14 | $4.06M derived: sum of 2 quarters · filed 2020-03-26 | $5.25M derived: sum of 3 quarters · filed 2020-03-26 | $6.43M derived: sum of 4 quarters · filed 2020-03-26 | |
| 2017-12-31 | $3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $4.32M derived: sum of 2 quarters · filed 2020-03-26 | $5.51M derived: sum of 3 quarters · filed 2020-03-26 | $6.78M 10-K · filed 2020-03-26 | |
| 2017-09-30 | $1.19M 10-Q · filed 2018-11-14 | $2.37M derived: sum of 2 quarters · filed 2018-11-14 | $3.65M 10-Q · filed 2018-11-14 | $4.80M derived: sum of 4 quarters · filed 2019-03-26 | |
| 2017-06-30 | $1.18M 10-Q · filed 2018-08-14 | $2.46M 10-Q · filed 2018-08-14 | $3.61M derived: sum of 3 quarters · filed 2019-03-26 | $4.84M derived: sum of 4 quarters · filed 2019-03-26 | |
| 2017-03-31 | $1.28M 10-Q · filed 2018-05-15 | $2.43M derived: sum of 2 quarters · filed 2019-03-26 | $3.65M derived: sum of 3 quarters · filed 2019-03-26 | $5.03M derived: sum of 4 quarters · filed 2019-03-26 | |
| 2016-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $2.38M derived: sum of 2 quarters · filed 2019-03-26 | $3.75M derived: sum of 3 quarters · filed 2019-03-26 | $5.03M 10-K · filed 2019-03-26 | |
| 2016-09-30 | $1.22M 10-Q · filed 2017-11-14 | $2.60M derived: sum of 2 quarters · filed 2017-11-14 | $3.88M 10-Q · filed 2017-11-14 | $6.26M derived: sum of 4 quarters · filed 2018-03-20 | |
| 2016-06-30 | $1.37M 10-Q · filed 2017-08-14 | $2.65M 10-Q · filed 2017-08-14 | $5.04M derived: sum of 3 quarters · filed 2018-03-20 | $6.09M derived: sum of 4 quarters · filed 2018-03-20 | |
| 2016-03-31 | $1.28M 10-Q · filed 2017-05-11 | $3.67M derived: sum of 2 quarters · filed 2018-03-20 | $4.72M derived: sum of 3 quarters · filed 2018-03-20 | $5.53M derived: sum of 4 quarters · filed 2018-03-20 | |
| 2015-12-31 | $2.39M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-20 | $3.44M derived: sum of 2 quarters · filed 2018-03-20 | $4.25M derived: sum of 3 quarters · filed 2018-03-20 | $4.86M 10-K · filed 2018-03-20 | |
| 2015-09-30 | $1.05M 10-Q · filed 2016-11-14 | $1.87M derived: sum of 2 quarters · filed 2016-11-14 | $2.47M 10-Q · filed 2016-11-14 | $3.48M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-06-30 | $816.00K 10-Q · filed 2016-08-10 | $1.42M 10-Q · filed 2016-08-10 | $2.42M derived: sum of 3 quarters · filed 2017-03-16 | $2.90M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-03-31 | $603.00K 10-Q · filed 2016-05-11 | $1.61M derived: sum of 2 quarters · filed 2017-03-16 | $2.08M derived: sum of 3 quarters · filed 2017-03-16 | $2.25M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2014-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $1.48M derived: sum of 2 quarters · filed 2017-03-16 | $1.65M derived: sum of 3 quarters · filed 2017-03-16 | $1.79M 10-K · filed 2017-03-16 | |
| 2014-09-30 | $474.00K 10-Q · filed 2015-11-10 | $639.00K derived: sum of 2 quarters · filed 2015-11-10 | $785.00K 10-Q · filed 2015-11-10 | ||
| 2014-06-30 | $165.00K 10-Q · filed 2015-08-12 | $312.00K 10-Q · filed 2015-08-12 | |||
| 2014-03-31 | $146.00K 10-Q · filed 2015-06-18 | ||||
| 2013-12-31 | $155.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |